Publications indexed to the term Neurofibromatosis 2
| Faculty | Title |
|---|---|
| 1 | Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. (Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group) Discov Med 2014 Dec;18(101):323-30 11 Citations |
| 1 | NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. (Schroeder RD, Angelo LS, Kurzrock R) Oncotarget 2014 Jan 15;5(1):67-77 59 Citations |
| 1 | Surgical removal of an atypical macular epiretinal membrane in neurofibromatosis type 2: clinicopathologic correlation and visual outcome. (Han DP, Chin M, Simons KB, Albert DM) Arch Ophthalmol 2012 Oct;130(10):1337-9 7 Citations |
| 1 | Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. (Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R) J Clin Oncol 2012 Feb 10;30(5):e64-8 42 Citations |
| 1 | Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. (Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R) Mol Cancer Ther 2011 Nov;10(11):2094-103 31 Citations |
| 1 | Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. (Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M) Clin Cancer Res 2009 Aug 15;15(16):5032-5039 71 Citations |
